Dev Kant Shandilya is having 20 years of experience in the field of Mass spectrometry and Analytical chemistry related to Research and Development of Pharmaceuticals. At present, he is working as the team lead in Analytical research and development section in Pharmaceuticals company. Ltd. He is expected in analytical research related to various phases of the drug development cycle. He is familiar with impurity profiling studies, metabolite profiling, de-novo sequencing of peptides using LC-MS/MS (Triple quadrupole & HR-MS/MS), GC-MS/MS, ICP-MS, and other advanced analytical instruments. He has completed his M.S in Analytical Chemistry in 1998 and recently he submitted his Ph.D. thesis in Mass spectrometry – Rational workflows. He published 5 publications in the field of Mass spectrometry (1- poster presentation, 1-review article and 4-research paper).
Prediction of the Fragmentation Pathway of Atorvastatin De-Protonated Ion